Novel Gene Therapies to Mitigate Neurotoxicity for Improved Treatment of Neurodegenerative Disease

 

Executive Summary

 

Dysfunction of the kynurenine pathway has been linked to Parkinson’s disease, Alzheimer’s disease, ALS, Huntington’s disease, brain ischemia, CNS infections, autoimmune disorders, mood disorders, and schizophrenia. If this pathway could be manipulated neuroprotection could be achieved. 

 

Description of Technology

 

MSU researchers have developed a variety of gene therapy vectors to manipulate the kynurenine pathway. This novel technology utilizes adeno-associated viral vectors to overexpress an kynurenine pathway-modulating enzyme in a cell-specific manner in various cell populations in the brains. This involves using novel viral vectors that are designed to divert the kynurenine pathway into a neuroprotective mode. This approach thus provides a potential neurorestorative and/or neuroprotective environment.

 

Key Benefits

  • Neuroprotectant for a plethora of neurological disorders
  • Cell Specific Targeting: Unique library of viral vectors aims at precisely targeting specific cells
  • Modulating a normal cellular pathway, thus, no ectopic genes will be expressed.

 

Applications

  • Treatment of multiple neurodegenerative diseases
  • Personalized medicine: Ability to treat patients based on their individual disease

  

Patent Status: 

 

Under review 

 

Licensing Rights Available

 

Full licensing rights available

 

Inventors: Fredric Manfredsson, Lena Brundin

 

Tech ID: TEC2015-0048

 

Alternative contact due to temporary leave:

 

Nina (Isi) Davis, Technology Marketing Manager, email: davisnin@msu.edu, phone (direct): (517)884-1829. 

 

Patent Information:

Category(s):

For Information, Contact:

Randy Ramharack
Technology Manager
Michigan State University
ramharac@msu.edu
Keywords: